Registries supporting new drug applications

PURPOSE: Knowledge of the benefits and risks of new drugs is incomplete at the time of marketing approval. Registries offer the possibility for additional, post‐approval, data collection. For all new drugs, which were approved in the European Union between 2007 and 2010, we reviewed the frequency, t...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonker, Carla J., van den Berg, H. Marijke, Kwa, Marcel S.G., Hoes, Arno W., Mol, Peter G.M.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2017
Materias:
Original Reports
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725674/
https://www.ncbi.nlm.nih.gov/pubmed/28983992
http://dx.doi.org/10.1002/pds.4332

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5725674/
https://www.ncbi.nlm.nih.gov/pubmed/28983992
http://dx.doi.org/10.1002/pds.4332

Ejemplares similares